The pleiotropic effects of CDKI-73 likely have important ramifications for prostate cancer treatment: i) they may mitigate the ability of cancer cells to effectively develop resistance mechanisms; and ii) they would be expected to potentiate the activity of standard-of-care AR-targeted therapies. The gene discussed is AR; the disease is Familial prostate cancer.